Biosimilar and Biologics Market, By Product Type (Biologics and Biosimilars), By Application, By Distribution, By Manufacturing Type, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4154
|
Published Date
July 2025
|
Pages
269
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Biosimilar and Biologics Market size was valued at US$ 556,309.44 Million in 2024, expanding at a CAGR of 7.81% from 2025 to 2032.
The biosimilars and biologics market is one of the fastest-growing segments within the global pharmaceutical industry. Biologics—complex, large molecules or molecular mixtures derived from living cells—are used for the treatment, diagnosis, and prevention of various diseases. These include monoclonal antibodies, vaccines, and recombinant proteins. Driven by advancements in biotechnology, the increasing prevalence of chronic diseases, patent expirations of major biologic drugs, and rising healthcare costs, the market is undergoing significant and rapid transformation.
Biosimilar and Biologics Market- Market Dynamics
Patent Expiry of Blockbuster Biologics
A major growth driver in the biosimilars market is the expiration of patents on key biologic drugs, often referred to as “blockbusters,” which generate billions in annual sales. Once these patents expire, biosimilar manufacturers can develop and introduce more affordable alternatives. For example, Adalimumab (Humira)—one of the world’s top-selling biologics used to treat rheumatoid arthritis and Crohn’s disease—generated over $20 billion in annual revenue before biosimilars entered the market. The patent expirations of blockbuster biologics fundamentally fuel the biosimilars market by fostering competition, lowering drug prices, and expanding patient access to life-saving therapies. Globally, governments are actively supporting this shift; for instance, the U.S. FDA has approved over 40 biosimilars since 2015 to promote affordable treatment options, while the European Medicines Agency (EMA) has implemented streamlined regulatory pathways to accelerate biosimilar approvals across Europe. This trend is expected to continue throughout the next decade, as more biologics lose exclusivity, driving significant growth in biosimilar development and adoption worldwide.
Biosimilar and Biologics Market- Segmentation Analysis:
The Global Biosimilar and Biologics Market is segmented on the basis of Product Type, Application, Distribution, Manufacturing Type, and Region.
The market for biologic therapies is broadly segmented into two product types: biologics and biosimilars. Biologics are original, complex medicines derived from living organisms and are primarily used to treat serious conditions such as cancer and autoimmune disorders. These therapies have transformed treatment paradigms by targeting specific disease mechanisms. Biosimilars, on the other hand, are highly similar, lower-cost versions of approved biologics, developed once the original product’s patent expires. They offer comparable safety and efficacy, providing more affordable treatment options and increasing patient access. Governments worldwide are actively supporting the biosimilar market to reduce healthcare costs; for example, the U.S. Food and Drug Administration (FDA) has established a robust regulatory pathway for biosimilar approvals to promote competition and lower drug prices.
The market is also divided based on application areas including oncology, infectious diseases, autoimmune diseases (such as rheumatoid arthritis and psoriasis), blood disorders (like anemia and hemophilia), diabetes, growth hormone deficiency, ophthalmic disorders (e.g., macular degeneration), and other conditions such as rare diseases and fertility treatments. Oncology stands out as the largest and fastest-growing segment due to the high global burden of cancer, driven by aging populations, lifestyle factors, and advancements in diagnostics. Biologics—especially monoclonal antibodies and targeted therapies—have revolutionized cancer treatment by providing personalized and more effective options with fewer side effects compared to traditional chemotherapy. This focus is reflected in substantial R&D investments, clinical trials, and regulatory approvals concentrated in oncology. Governments globally, including agencies like the National Cancer Institute (NCI) in the United States, continue to prioritize cancer research and support precision medicine initiatives, underscoring oncology’s sustained dominance and growth potential in the biologics and biosimilars market.
Biosimilar and Biologics Market- Geographical Insights
The biosimilars and biologics market demonstrates diverse growth trends across various geographic regions. North America, particularly the United States, commands a significant share of the biologics market, supported by its advanced healthcare infrastructure, substantial R&D investments, and the presence of major pharmaceutical companies. Although biosimilar adoption in the U.S. was initially slow due to regulatory complexities and market challenges, it has gained momentum following the patent expirations of blockbuster drugs like Humira. Europe remains the most mature and established biosimilars market, propelled by cost-containment policies, robust regulatory support from the European Medicines Agency (EMA), and strong acceptance among physicians and patients.
The Asia-Pacific region is the fastest-growing market, with countries such as India, China, and South Korea emerging as key biosimilar producers. This expansion is fueled by large patient populations, improving healthcare access, and evolving regulatory frameworks. For instance, China’s “Healthy China 2030” initiative prioritizes biosimilar development to improve healthcare affordability, while India’s government has implemented fast-track approvals to encourage biosimilar manufacturing. In Latin America, the market is steadily growing as nations modernize healthcare infrastructure and promote biosimilar adoption to reduce public healthcare expenditures. Meanwhile, the Middle East and Africa are emerging markets characterized by increasing demand for affordable biologic therapies, although challenges related to access and infrastructure persist. Globally, government initiatives strongly support the biosimilars market’s expansion. According to the U.S. FDA, biosimilars could save the American healthcare system up to $100 billion over the next decade. The European Commission estimates that biosimilars have already contributed to saving around €33 billion since 2006 across Europe by increasing competition and reducing prices. Additionally, the World Health Organization advocates for biosimilar use to enhance treatment accessibility in low- and middle-income countries. Overall, while Europe leads in biosimilar adoption, North America and Asia-Pacific are positioned to drive substantial market growth in the coming years.
Biosimilar and Biologics Market- Competitive Landscape:
The competitive landscape of the biosimilars and biologics market is marked by intense rivalry among a combination of established pharmaceutical giants and emerging biotech firms. Leading companies such as Amgen, Pfizer, Roche, Novartis (Sandoz), Samsung Bioepis, Biocon, Celltrion, and Mylan (Viatris) dominate the sector by leveraging robust R&D capabilities, extensive manufacturing infrastructure, and global distribution networks to sustain and grow their market share. These players are heavily investing in the development of biosimilars for high-demand biologics whose patents have expired or are approaching expiration.
Competition extends beyond pricing and encompasses factors such as product quality, regulatory approvals, patent strategies, and marketing efforts aimed at building trust among physicians and patients. Strategic partnerships, collaborations, and mergers and acquisitions are also prevalent, helping companies strengthen their pipelines and expand market access. Additionally, regional variations in regulatory requirements and market access complicate the competitive environment, influencing how biosimilar products are positioned globally. Looking ahead, innovation in bioprocessing technologies and the development of tailored therapies will be critical for companies seeking to remain competitive in this rapidly growing market.
Recent Developments:
- In March 2025, Fresenius Kabi received U.S. FDA approval for two denosumab biosimilars, Conexxence and Bomyntra. These biosimilars are now approved for the same indications as the reference drugs, Prolia and Xgeva, respectively. This milestone broadens treatment options for patients with osteoporosis and cancer-related bone loss, further contributing to the increasing acceptance of biosimilars in the U.S. market.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOSIMILAR AND BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amgen Inc.
- Novartis AG (Sandoz)
- Pfizer Inc.
- Roche Holding AG
- Samsung Bioepis
- Biocon Ltd.
- Mylan N.V. (Viatris)
- Celltrion Inc.
- Fresenius Kabi
- Boehringer Ingelheim
- Cipla Limited
- Teva Pharmaceutical Industries Ltd.
- Sandoz (a Novartis division)
- Dr. Reddy’s Laboratories
- Intas Pharmaceuticals Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- LG Chem Life Sciences
- Pfizer Inc.
- Hetero Drugs Limited
- Oncobiologics, Inc.
- Others
GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- Biologics:
- Monoclonal Antibodies (mAbs)
- Vaccines
- Recombinant Hormones (e.g., insulin, human growth hormone)
- Therapeutic Proteins (e.g., erythropoietin, interferons)
- Blood Products
- Gene Therapy
- Cell Therapy
- Biosimilars:
- Monoclonal Antibodies Biosimilars
- Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
- Erythropoietin Biosimilars
- Filgrastim and Pegfilgrastim Biosimilars
- Infliximab, Adalimumab, Trastuzumab Biosimilars
- Interferons Biosimilars
GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Oncology
- Infectious Diseases
- Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
- Blood Disorders (e.g., anemia, hemophilia)
- Diabetes
- Growth Hormone Deficiency
- Ophthalmic Disorders (e.g., macular degeneration)
- Others (e.g., rare diseases, fertility treatments)
GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY MANUFACTURING TYPE- MARKET ANALYSIS, 2019 - 2032
- In-house Manufacturing
- Contract Manufacturing Organizations (CMOs)
GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Biosimilar and Biologics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Biosimilar and Biologics Market Snippet by Product Type
2.1.2. Biosimilar and Biologics Market Snippet by Application
2.1.3. Biosimilar and Biologics Market Snippet by Distribution
2.1.4. Biosimilar and Biologics Market Snippet by Manufacturing Type
2.1.5. Biosimilar and Biologics Market Snippet by Country
2.1.6. Biosimilar and Biologics Market Snippet by Region
2.2. Competitive Insights
3. Biosimilar and Biologics Key Market Trends
3.1. Biosimilar and Biologics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Biosimilar and Biologics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Biosimilar and Biologics Market Opportunities
3.4. Biosimilar and Biologics Market Future Trends
4. Biosimilar and Biologics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Biosimilar and Biologics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Biosimilar and Biologics Market Landscape
6.1. Biosimilar and Biologics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Biosimilar and Biologics Market – By Product Type
7.1. Overview
7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
7.1.2. Biologics:
7.1.2.1. Monoclonal Antibodies (mAbs)
7.1.2.2. Vaccines
7.1.2.3. Recombinant Hormones (e.g., insulin, human growth hormone)
7.1.2.4. Therapeutic Proteins (e.g., erythropoietin, interferons)
7.1.2.5. Blood Products
7.1.2.6. Gene Therapy
7.1.2.7. Cell Therapy
7.1.3. Biosimilars:
7.1.3.1. Monoclonal Antibodies Biosimilars
7.1.3.2. Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
7.1.3.3. Erythropoietin Biosimilars
7.1.3.4. Filgrastim and Pegfilgrastim Biosimilars
7.1.3.5. Infliximab, Adalimumab, Trastuzumab Biosimilars
7.1.3.6. Interferons Biosimilars
8. Biosimilar and Biologics Market – By Application
8.1. Overview
8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
8.1.2. Oncology
8.1.3. Infectious Diseases
8.1.4. Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
8.1.5. Blood Disorders (e.g., anemia, hemophilia)
8.1.6. Diabetes
8.1.7. Growth Hormone Deficiency
8.1.8. Ophthalmic Disorders (e.g., macular degeneration)
8.1.9. Others (e.g., rare diseases, fertility treatments)
9. Biosimilar and Biologics Market – By Distribution
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
9.1.2. Hospital Pharmacies
9.1.3. Online Pharmacies
9.1.4. Retail Pharmacies
10. Biosimilar and Biologics Market – By Manufacturing Type
10.1. Overview
10.1.1. Segment Share Analysis, By Manufacturing Type, 2024 & 2032 (%)
10.1.2. In-house Manufacturing
10.1.3. Contract Manufacturing Organizations (CMOs)
11. Biosimilar and Biologics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Biosimilar and Biologics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Biosimilar and Biologics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Biosimilar and Biologics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Biosimilar and Biologics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Biosimilar and Biologics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Biosimilar and Biologics Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Amgen Inc.
12.2.2. Novartis AG (Sandoz)
12.2.3. Pfizer Inc.
12.2.4. Roche Holding AG
12.2.5. Samsung Bioepis
12.2.6. Biocon Ltd.
12.2.7. Mylan N.V. (Viatris)
12.2.8. Celltrion Inc.
12.2.9. Fresenius Kabi
12.2.10. Boehringer Ingelheim
12.2.11. Cipla Limited
12.2.12. Teva Pharmaceutical Industries Ltd.
12.2.13. Sandoz (a Novartis division)
12.2.14. Dr. Reddy’s Laboratories
12.2.15. Intas Pharmaceuticals Ltd.
12.2.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
12.2.17. LG Chem Life Sciences
12.2.18. Pfizer Inc.
12.2.19. Hetero Drugs Limited
12.2.20. Oncobiologics, Inc.
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
